1,371
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Safety of bazedoxifene in Korean women with post-menopausal osteoporosis: a post-marketing surveillance study (PMSS)

, , , &
Pages 1001-1008 | Received 25 Feb 2019, Accepted 07 Aug 2019, Published online: 14 Aug 2019

References

  • Cole Z, Dennison E, Cooper C. Update on the treatment of post-menopausal osteoporosis. Br Med Bull. 2008;86:129–143.
  • Garnero P. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther. 2008;12(3):157–170.
  • Jang HD, Hong JY, Han K, et al. Relationship between bone mineral density and alcohol intake: a nationwide health survey analysis of postmenopausal women. PLoS One. 2017 Jun 29;12(6):e0180132.
  • Lin JT, Lane JM. Osteoporosis: a review. Clin Orthop Relat Res. 2004 Aug;425:126–134.
  • Kim JW, Jeon Y-J, Baek D-H, et al. Percentage of the population at high risk of osteoporotic fracture in South Korea: analysis of the 2010 fifth Korean national health and nutrition examination survey data. Osteoporos Int. 2014 Apr;25(4):1313–1319.
  • Komm BS, Lyttle CR. Developing a SERM: Stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann N Y Acad Sci. 2001 Dec;949:317–326.
  • Xu L, Tsai KS, Kim GS, et al. Efficacy and safety of bazedoxifene in postmenopausal Asian women. Osteoporos Int. 2011 Feb;22(2):559–565.
  • Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res. 2008 Apr;23(4):525–535.
  • Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008 Dec;23(12):1923–1934.
  • Ministry of Food and Drug Safety, Korea. Bezadoxifene Information. [cited 2019 Feb 24]. Available from: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=201110095
  • Lippuner K, Buchard PA, De Geyter C, et al. Recommendations for raloxifene use in daily clinical practice in the Swiss setting. Eur Spine J. 2012 Dec;21(12):2407–2417.
  • Itabashi A, Yoh K, Chines AA, et al. Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal Japanese women with osteoporosis. J Bone Miner Res. 2011 Mar;26(3):519–529.
  • de Villiers TJ, Chines AA, Palacios S, et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int. 2011 Feb;22(2):567–576.
  • Ki-Chan A. Selective estrogen receptor modulators. Asian Spine J. 2016 Aug;10(4):787–791.
  • Takeuchi Y, Hamaya E, Taketsuna M, et al. Safety of 3-year raloxifene treatment in Japanese postmenopausal women aged 75 years or older with osteoporosis: a postmarketing surveillance study. Menopause. 2015 Oct;22(10):1134–1137.